#NIH clinical trial of investigational vaccine for #COVID_19 begins
3460 Friday, 27 March, 2020, 11:25 A Phase 1 clinical trial evaluating an investigational vaccine designed to protect against coronavirus disease 2019 (COVID-19) has begun at Kaiser Permanente Washington Health Research Institute (KPWHRI) in Seattle. The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, is funding the trial. KPWHRI is part of NIAID’s Infectious Diseases Clinical Research Consortium. The open-label trial will enroll 45 healthy adult volunteers ages 18 to 55 years over approximately 6 weeks. The first participant received the investigational vaccine today. The study is evaluating different doses of the experimental vaccine for safety and its ability to induce an immune response in participants. This is the first of multiple steps in the clinical trial process for evaluating the potential benefit of the vaccine. |
SpaceX Starship ‘Lost’ After Reaching Space During Third Test Flight
649914.03.2024, 20:27Neuralink's first human patient can control mouse through thinking, says Elon Musk
934620.02.2024, 15:24A Bronze Age lip-paint from southeastern Iran (photo)
1057506.02.2024, 20:24Apple thinks iOS 18 might be the ‘biggest’ iOS update ever
1073003.02.2024, 20:06Elon Musk's Neuralink implants brain chip in first human (video)
1054930.01.2024, 10:30Nokia smartphone brand will soon disappear: Why has it failed to gain a place in the market?
1217118.01.2024, 23:48For the first time in 30 years, your keyboard is about to be changed (video)
1357605.01.2024, 17:24Coronal mass ejection from colossal New Year's Eve solar flare will strike Earth today
1421305.01.2024, 00:18